MarketCap
Facebook
X
Telegram
Cue Biopharma Market Cap | CUE
As of September 14, 2026 Cue Biopharma has a market cap of $ 2.9 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 M | 51.3 M | 86.5 M | 108 M | 354 M | 388 M | 337 M | 101 M | 311 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 388 M | 29.4 M | 196 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
2 B | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
247 M | $ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
5.13 B | $ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
545 M | $ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
318 M | $ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
114 M | $ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
198 B | $ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
5.8 B | $ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
4.31 B | $ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
400 B | $ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
1.52 B | $ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
214 M | $ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
4.97 M | $ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
1.42 M | $ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
1.62 B | $ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
312 M | $ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
255 K | $ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
869 M | $ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
308 M | $ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
30.9 M | $ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
73.6 M | $ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
97.8 M | $ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
1.86 B | $ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
426 M | $ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
30.6 B | $ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
8.67 B | $ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
13.1 B | $ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
2.25 B | $ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
351 M | $ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
125 M | $ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
3.2 B | $ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
29.4 B | $ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
5.65 B | $ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
122 B | $ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
556 M | $ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
2.78 B | $ 4.35 | 1.13 % | $ 953 M | Britain |